Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 200

1.

Usefulness of HKLC versus BCLC staging system in a European HCC cohort.

Adhoute X, Penaranda G, Bronowicki JP, Raoul JL.

J Hepatol. 2014 Sep 3. pii: S0168-8278(14)00622-9. doi: 10.1016/j.jhep.2014.08.035. [Epub ahead of print] No abstract available.

PMID:
25194894
[PubMed - as supplied by publisher]
2.

Treatment of intermediate-stage hepatocellular carcinoma.

Forner A, Gilabert M, Bruix J, Raoul JL.

Nat Rev Clin Oncol. 2014 Sep;11(9):525-35. doi: 10.1038/nrclinonc.2014.122. Epub 2014 Aug 5.

PMID:
25091611
[PubMed - in process]
3.

Distant lymph node metastases in gastroesophageal junction adenocarcinoma: impact of endoscopic ultrasound-guided fine-needle aspiration.

Araujo J, Bories E, Caillol F, Pesenti C, Guiramand J, Poizat FF, Monges G, Ries P, Raoul JL, Delpero JR, Giovannini M.

Endosc Ultrasound. 2013 Jul;2(3):148-52. doi: 10.7178/eus.06.006.

PMID:
24949383
[PubMed]
Free PMC Article
4.

How to define transarterial chemoembolization failure or refractoriness: a European perspective.

Raoul JL, Gilabert M, Piana G.

Liver Cancer. 2014 May;3(2):119-24. doi: 10.1159/000343867. Review.

PMID:
24945002
[PubMed]
Free PMC Article
5.

Bazex syndrome revealing a gastric cancer.

Robert M, Gilabert M, Rahal S, Ries P, Raoul JL.

Case Rep Oncol. 2014 Apr 30;7(1):285-7. doi: 10.1159/000362787. eCollection 2014 Jan.

PMID:
24926258
[PubMed]
Free PMC Article
6.

[Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings?].

Barbare JC, Franco D, André T, Bronowicki JP, Merle P, Péron JM, Raoul JL, Seitz JF, Ychou M.

Bull Cancer. 2014 Jun;101(6):558-63. doi: 10.1684/bdc.2014.1918. French.

PMID:
24898934
[PubMed - indexed for MEDLINE]
7.

Radio(chemo)therapy in Elderly Patients with Esophageal Cancer: A Feasible Treatment with an Outcome Consistent with Younger Patients.

Rochigneux P, Resbeut M, Rousseau F, Bories E, Raoul JL, Poizat F, Moureau-Zabotto L.

Front Oncol. 2014 May 12;4:100. doi: 10.3389/fonc.2014.00100. eCollection 2014.

PMID:
24860783
[PubMed]
Free PMC Article
8.

One case of intrahepatic cholangiocarcinoma amenable to resection after radioembolization.

Servajean C, Gilabert M, Piana G, Monges G, Delpero JR, Brenot I, Raoul JL.

World J Gastroenterol. 2014 May 7;20(17):5131-4. doi: 10.3748/wjg.v20.i17.5131.

PMID:
24803830
[PubMed - in process]
Free PMC Article
9.

Acute immune hematological complication of oxaliplatin. A series of 3 cases.

Garciaz S, Oziel-Taieb S, Dermeche S, Ries P, Vessaud J, Raoul JL.

Tumori. 2014 Jan-Feb;100(1):e17-9. doi: 10.1700/1430.15831.

PMID:
24675502
[PubMed - indexed for MEDLINE]
10.

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group.

Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18.

PMID:
24556041
[PubMed - indexed for MEDLINE]
11.

Impact of radiotherapy in the management of locally advanced extrahepatic cholangiocarcinoma.

Moureau-Zabotto L, Turrini O, Resbeut M, Raoul JL, Giovannini M, Poizat F, Piana G, Delpero JR, Bertucci F.

BMC Cancer. 2013 Dec 3;13:568. doi: 10.1186/1471-2407-13-568.

PMID:
24299517
[PubMed - indexed for MEDLINE]
Free Article
12.

In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results.

Pracht M, Edeline J, Lepareur N, Lenoir L, Ardisson V, Clement B, Raoul JL, Audrain O, Boucher E, Garin E.

Anticancer Res. 2013 Sep;33(9):3871-7.

PMID:
24023322
[PubMed - indexed for MEDLINE]
13.

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW.

J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26.

PMID:
23980090
[PubMed - indexed for MEDLINE]
14.

Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL.

J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26.

PMID:
23980084
[PubMed - indexed for MEDLINE]
15.

Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective.

Colombo M, Raoul JL, Lencioni R, Galle PR, Zucman-Rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P.

Eur J Gastroenterol Hepatol. 2013 Jun;25(6):639-51. doi: 10.1097/MEG.0b013e32835e33bb. Review.

PMID:
23628963
[PubMed - indexed for MEDLINE]
16.

Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept.

Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, Sulpice L, Boudjema K, Mesbah M, Guillygomarc'h A, Quehen E, Pracht M, Raoul JL, Clement B, Rolland Y, Boucher E.

Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1057-68. doi: 10.1007/s00259-013-2395-x. Epub 2013 Apr 24.

PMID:
23613103
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

[Palliative treatment for hepatocellular carcinoma].

Raoul JL, Gilabert M, Oziel-Taïeb S, Giovannini M.

Rev Prat. 2013 Feb;63(2):233-6. Review. French.

PMID:
23513793
[PubMed - indexed for MEDLINE]
18.

Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?

Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, Pracht M, Raoul JL, Clément B, Garin E, Boucher E.

Ann Surg Oncol. 2013 Aug;20(8):2518-25. doi: 10.1245/s10434-013-2906-9. Epub 2013 Mar 15.

PMID:
23494107
[PubMed - indexed for MEDLINE]
19.

Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results.

Pracht M, Edeline J, Lenoir L, Latournerie M, Mesbah H, Audrain O, Rolland Y, Clément B, Raoul JL, Garin E, Boucher E.

Int J Hepatol. 2013;2013:827649. doi: 10.1155/2013/827649. Epub 2013 Feb 17.

PMID:
23476792
[PubMed]
Free PMC Article
20.

Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.

Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, Raoul JL, Sangro B.

Semin Liver Dis. 2012 Nov;32(4):348-59. doi: 10.1055/s-0032-1329906. Epub 2013 Feb 8. Review.

PMID:
23397536
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk